Inclusion Criteria:

- Patients must have histologically or cytologically confirmed Stage III-IV disease
comprised of T3 or T4 N0-2 lesions of the oral cavity, oropharynx, hypopharynx, and
larynx.

- No previous radiation therapy or chemotherapy.

- No evidence of distant metastatic disease.

- Age > 18.

- Karnofsky performance status of > 60 (ECOG 2).

- ANC > 1000, platelets > 100,000, calculated or 24-hour creatinine clearance > 60.

- Study-specific informed consent form.

- Protocol treatment must begin < 8 weeks of diagnostic biopsy.

- Ability to understand and the willingness to sign a written informed consent
document.

- Patients with surgically cured secondary malignancy who have been disease free > 5
years are eligible.

Exclusion Criteria:

- Radiologic evidence of bone destruction.

- Previous or concurrent head and neck primaries.

- Prior surgery to study site other than biopsy.

- Patients receiving any other investigational agents.

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to agents used in the study.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- Pregnant women are excluded from this study because treatments and agents have the
potential for teratogenic or abortifacient effects. For this reason, women of
child-bearing potential and men must agree to use adequate contraception (hormonal or
barrier method of birth control; abstinence) prior to study entry and for the
duration of study participation. Should a woman become pregnant or suspect she is
pregnant while participating in this study, she should inform her treating physician
immediately.

- History of a prior or concomitant malignancy (other than carcinoma in situ of the
cervix, basal cell or squamous cell carcinoma of the skin).